DIGESTIVE AND LIVER DISEASE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2020-10-16 ms9476632540558124

审稿速度:1.0 | 投稿命中率:25.0
经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。

151 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2023-04-01 ms4000000223433444 来自山东省

digestive and liver disease是需要所有读者认证吗？求助

71 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2022-10-09 Eugene Deng

请问这个杂志可以共一吗

66 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2020-08-06 钻子，锤子，锯子

几个月了

159 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2024-04-25 ms7000001433627956 来自山东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：胆管癌
经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了

2 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2024-04-18 ms9000002054407114 来自河北

偏重的研究方向：肝细胞癌
经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？

17 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2023-09-15 ms6000000656125557 来自云南省

这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗

57 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2023-04-17 ms1000002026392296 来自甘肃省

偏重的研究方向：肝细胞癌;肝病
经验分享：请问大家，这个杂志接受meta吗

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2016-10-10 紫微愿

审稿速度:6.0 | 投稿命中率:50.0
经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。

402 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=892361, encodeId=f4ba89236131, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：上午十点多刚投出去，晚上十二点火速拒稿，这个效率我是不是应该开心。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=ms9476632540558124, createdTime=Fri Oct 16 00:21:53 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123079, encodeId=fa9521230e9f9, content=digestive and liver disease是需要所有读者认证吗？求助, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200916/86250b9f6f2640758fbe808a053d0193/4ff28ecd75a84be4a6872cc3504359aa.jpg, createdBy=277e5418822, createdName=ms4000000223433444, createdTime=Sat Apr 01 00:27:15 CST 2023, time=2023-04-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2092705, encodeId=18242092e057e, content=请问这个杂志可以共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75415572385, createdName=Eugene Deng, createdTime=Sun Oct 09 18:42:11 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806626, encodeId=6b4580662609, content=几个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59f5403928, createdName=钻子，锤子，锯子, createdTime=Thu Aug 06 20:06:20 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200441, encodeId=8099220044128, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：胆管癌 经验分享：2023年4月初投的，月底给的返修，非常快，意见也比较中肯，补了很多实验，2个月返回去，一个周之内二修，返回去之后就接收了。接收之后proof也非常快，proof结束2天online了，选了非OA，23年8月28号online的，今年3月份publish，下个月应该能开出检索证明了。同组也中了一篇，选的OA，今年1月接收，到现在只是online了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0f96148029, createdName=ms7000001433627956, createdTime=Thu Apr 25 21:51:11 CST 2024, time=2024-04-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2199123, encodeId=960b2199123c3, content=偏重的研究方向：肝细胞癌 经验分享：11号投的，当天给了稿号，目前还没消息，是准备送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe768803134, createdName=ms9000002054407114, createdTime=Thu Apr 18 14:42:04 CST 2024, time=2024-04-18, status=1, ipAttribution=河北), GetPortalCommentsPageByObjectIdResponse(id=2157904, encodeId=5cb0215e9042e, content=这个期刊接受case report吗，我看images of the month栏目是以case report 的形式，有什么区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d496480466, createdName=ms6000000656125557, createdTime=Fri Sep 15 22:33:37 CST 2023, time=2023-09-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2126581, encodeId=caa3212658106, content=偏重的研究方向：肝细胞癌;肝病 经验分享：请问大家，这个杂志接受meta吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730f6151830, createdName=ms1000002026392296, createdTime=Mon Apr 17 20:52:50 CST 2023, time=2023-04-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=528079, encodeId=a2505280e943, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：4月7号投出去，一审挺快的，不到一个月，大修1次，小修1次后于8月16号接收。挺顺利的。编辑和审稿人很负责，很友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61c21641541, createdName=紫微愿, createdTime=Mon Oct 10 15:39:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182501, encodeId=d58f1182501a0, content=偏重的研究方向：消化;肝细胞癌;肝癌 经验分享：请问这个杂志收综述嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85476317, createdName=ms6000001456464025, createdTime=Sun Jan 09 12:30:45 CST 2022, time=2022-01-09, status=1, ipAttribution=)]

2022-01-09 ms6000001456464025

偏重的研究方向：消化;肝细胞癌;肝癌
经验分享：请问这个杂志收综述嘛

53 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务